HCW Biologics Ownership 2024 | Who Owns HCW Biologics Now?

Overview RevenueFinancials Chart

Institutional Ownership

1.44%

Insider Ownership

52.30%

Retail Ownership

46.26%

Institutional Holders

3.00

HCW Biologics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
AVANTAX PLANNING PARTNERS, INC.	0.75%	0.01%	279,541	99,764	55.49%	180,863	Jun 30, 2024
HIGHTOWER ADVISORS, LLC	0.49%	0.00%	180,810	1,000	0.56%	117,000	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.46%	-	170,385	-3,899	-2.24%	110,269	Jun 30, 2024
CRESSET ASSET MANAGEMENT, LLC	0.35%	0.00%	131,990	-	-	85,398	Jun 30, 2024
PULLEN INVESTMENT MANAGEMENT, LLC	0.23%	0.05%	85,116	-	-	55,070	Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.23%	0.00%	84,700	-	-	54,801	Jun 30, 2024
HRT FINANCIAL LP	0.18%	0.00%	66,659	-6,454	-8.83%	43,000	Jun 30, 2024
BLACKROCK INC.	0.11%	-	42,662	-3,372	-7.33%	27,602	Jun 30, 2024
VANGUARD GROUP INC	0.10%	-	37,677	28	0.07%	24,377	Jun 30, 2024
AE WEALTH MANAGEMENT LLC	0.08%	0.00%	30,000	-	-	19,410	Jun 30, 2024
TWO SIGMA INVESTMENTS, LP	0.06%	-	22,480	-160	-0.71%	14,545	Jun 30, 2024
STATE STREET CORP	0.06%	-	21,446	-	-	13,876,000	Jun 30, 2024
NORTHERN TRUST CORP	0.03%	-	10,205	-	-	6,603,000	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.02%	0.00%	6,212	1,274	25.80%	4,019	Jun 30, 2024
UBS GROUP AG	0.01%	-	4,285	3,680	608.26%	2,772	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	156	-250	-61.58%	101	Jun 30, 2024
JPMORGAN CHASE & CO	-	-	-	-9	-100.00%	-	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-141	-100.00%	-	Jun 30, 2024

HCW Biologics's largest institutional shareholder is AVANTAX PLANNING PARTNERS, INC., holding 0.75% of the company's total share outstanding, currently valued at $180.86K. The top 10 institutional shareholders own together 2.98% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
PULLEN INVESTMENT MANAGEMENT, LLC	0.23%	0.05%	85,116	-	-	55,070	Jun 30, 2024
AVANTAX PLANNING PARTNERS, INC.	0.75%	0.01%	279,541	99,764	55.49%	180,863	Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.23%	0.00%	84,700	-	-	54,801	Jun 30, 2024
CRESSET ASSET MANAGEMENT, LLC	0.35%	0.00%	131,990	-	-	85,398	Jun 30, 2024
HRT FINANCIAL LP	0.18%	0.00%	66,659	-6,454	-8.83%	43,000	Jun 30, 2024
AE WEALTH MANAGEMENT LLC	0.08%	0.00%	30,000	-	-	19,410	Jun 30, 2024
HIGHTOWER ADVISORS, LLC	0.49%	0.00%	180,810	1,000	0.56%	117,000	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.02%	0.00%	6,212	1,274	25.80%	4,019	Jun 30, 2024
TWO SIGMA INVESTMENTS, LP	0.06%	-	22,480	-160	-0.71%	14,545	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.46%	-	170,385	-3,899	-2.24%	110,269	Jun 30, 2024
NORTHERN TRUST CORP	0.03%	-	10,205	-	-	6,603,000	Jun 30, 2024
UBS GROUP AG	0.01%	-	4,285	3,680	608.26%	2,772	Jun 30, 2024
BLACKROCK INC.	0.11%	-	42,662	-3,372	-7.33%	27,602	Jun 30, 2024
STATE STREET CORP	0.06%	-	21,446	-	-	13,876,000	Jun 30, 2024
VANGUARD GROUP INC	0.10%	-	37,677	28	0.07%	24,377	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	156	-250	-61.58%	101	Jun 30, 2024
JPMORGAN CHASE & CO	-	-	-	-9	-100.00%	-	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-141	-100.00%	-	Jun 30, 2024

The largest HCW Biologics shareholder by % of total assets is PULLEN INVESTMENT MANAGEMENT, LLC. The company owns 85.12K shares of HCW Biologics (HCWB), representing 0.05% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
AVANTAX PLANNING PARTNERS, INC.	0.75%	0.01%	279,541	99,764	55.49%	180,863	Jun 30, 2024
UBS GROUP AG	0.01%	-	4,285	3,680	608.26%	2,772	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.02%	0.00%	6,212	1,274	25.80%	4,019	Jun 30, 2024
HIGHTOWER ADVISORS, LLC	0.49%	0.00%	180,810	1,000	0.56%	117,000	Jun 30, 2024
VANGUARD GROUP INC	0.10%	-	37,677	28	0.07%	24,377	Jun 30, 2024
STATE STREET CORP	0.06%	-	21,446	-	-	13,876,000	Jun 30, 2024
NORTHERN TRUST CORP	0.03%	-	10,205	-	-	6,603,000	Jun 30, 2024
AE WEALTH MANAGEMENT LLC	0.08%	0.00%	30,000	-	-	19,410	Jun 30, 2024
CRESSET ASSET MANAGEMENT, LLC	0.35%	0.00%	131,990	-	-	85,398	Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.23%	0.00%	84,700	-	-	54,801	Jun 30, 2024
PULLEN INVESTMENT MANAGEMENT, LLC	0.23%	0.05%	85,116	-	-	55,070	Jun 30, 2024
JPMORGAN CHASE & CO	-	-	-	-9	-100.00%	-	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-141	-100.00%	-	Jun 30, 2024
TWO SIGMA INVESTMENTS, LP	0.06%	-	22,480	-160	-0.71%	14,545	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	156	-250	-61.58%	101	Jun 30, 2024
BLACKROCK INC.	0.11%	-	42,662	-3,372	-7.33%	27,602	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.46%	-	170,385	-3,899	-2.24%	110,269	Jun 30, 2024
HRT FINANCIAL LP	0.18%	0.00%	66,659	-6,454	-8.83%	43,000	Jun 30, 2024

As of Jun 30 2024, HCW Biologics's largest institutional buyer is AVANTAX PLANNING PARTNERS, INC.. The company purchased 99.76K stocks of HCWB, valued at $180.86K.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
HRT FINANCIAL LP	0.18%	0.00%	66,659	-6,454	-8.83%	43,000	Jun 30, 2024
GEODE CAPITAL MANAGEMENT, LLC	0.46%	-	170,385	-3,899	-2.24%	110,269	Jun 30, 2024
BLACKROCK INC.	0.11%	-	42,662	-3,372	-7.33%	27,602	Jun 30, 2024
BANK OF AMERICA CORP /DE/	0.00%	-	156	-250	-61.58%	101	Jun 30, 2024
TWO SIGMA INVESTMENTS, LP	0.06%	-	22,480	-160	-0.71%	14,545	Jun 30, 2024
WELLS FARGO & COMPANY/MN	-	-	-	-141	-100.00%	-	Jun 30, 2024
JPMORGAN CHASE & CO	-	-	-	-9	-100.00%	-	Jun 30, 2024
PULLEN INVESTMENT MANAGEMENT, LLC	0.23%	0.05%	85,116	-	-	55,070	Jun 30, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC	0.23%	0.00%	84,700	-	-	54,801	Jun 30, 2024
CRESSET ASSET MANAGEMENT, LLC	0.35%	0.00%	131,990	-	-	85,398	Jun 30, 2024
AE WEALTH MANAGEMENT LLC	0.08%	0.00%	30,000	-	-	19,410	Jun 30, 2024
NORTHERN TRUST CORP	0.03%	-	10,205	-	-	6,603,000	Jun 30, 2024
STATE STREET CORP	0.06%	-	21,446	-	-	13,876,000	Jun 30, 2024
VANGUARD GROUP INC	0.10%	-	37,677	28	0.07%	24,377	Jun 30, 2024
HIGHTOWER ADVISORS, LLC	0.49%	0.00%	180,810	1,000	0.56%	117,000	Jun 30, 2024
TOWER RESEARCH CAPITAL LLC (TRC)	0.02%	0.00%	6,212	1,274	25.80%	4,019	Jun 30, 2024
UBS GROUP AG	0.01%	-	4,285	3,680	608.26%	2,772	Jun 30, 2024
AVANTAX PLANNING PARTNERS, INC.	0.75%	0.01%	279,541	99,764	55.49%	180,863	Jun 30, 2024

As of Jun 30 2024, HCW Biologics's biggest institutional seller is HRT FINANCIAL LP. The company sold -6.45K shares of HCWB, valued at $43.00K.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
WELLS FARGO & COMPANY/MN	-	-	-	-141	-100.00%	-	Jun 30, 2024
JPMORGAN CHASE & CO	-	-	-	-9	-100.00%	-	Jun 30, 2024

HCW Biologics's largest sold out institutional shareholder by shares sold is WELLS FARGO & COMPANY/MN, sold -0.14K shares, valued at -, as of undefined.

HCW Biologics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
BRIDGEWAY FUNDS INC	0.04%	84,700	-	-	Mar 28, 2024
FIDELITY CONCORD STREET TRUST	0.00%	127,757	1,439	1.14%	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	37,649	-204,944	-84.48%	Mar 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	1,708	-	-	Jan 31, 2024
EQ ADVISORS TRUST	0.00%	3,382	-	-	Mar 31, 2024
iSHARES TRUST	0.00%	42,652	-1,124	-2.57%	Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST	0.00%	838	-	-	Mar 31, 2024

HCW Biologics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 84.70K shares, compromising 0.04% of its total assets.

HCW Biologics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 24	3	-84.21%
31 Mar, 24	19	5.56%
31 Dec, 23	18	28.57%
30 Sep, 23	14	16.67%
30 Jun, 23	12	-7.69%
31 Mar, 23	13	-7.14%
31 Dec, 22	14	27.27%
30 Sep, 22	11	-8.33%
30 Jun, 22	12	-
31 Mar, 22	12	9.09%
31 Dec, 21	11	37.50%
30 Sep, 21	8	-

As of 30 Jun 24, 3 institutions are holding HCW Biologics's shares, representing a decrease of -84.21% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 24	535,042	-51.36%
31 Mar, 24	1,100,110	3.30%
31 Dec, 23	1,064,955	4.94%
30 Sep, 23	1,014,821	1.46%
30 Jun, 23	1,000,256	14.36%
31 Mar, 23	874,657	11.99%
31 Dec, 22	781,012	19.33%
30 Sep, 22	654,478	14.95%
30 Jun, 22	569,364	5.32%
31 Mar, 22	540,609	46.50%
31 Dec, 21	369,016	129.83%
30 Sep, 21	160,563	-

HCW Biologics (HCWB) has 535.04K shares outstanding as of 30 Jun 24, down -51.36% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 24	1.44%	15.33%
31 Mar, 24	3.06%	34.85%
31 Dec, 23	2.96%	37.12%
30 Sep, 23	2.83%	36.37%
30 Jun, 23	2.79%	46.92%
31 Mar, 23	2.44%	51.39%
31 Dec, 22	2.18%	65.29%
30 Sep, 22	1.83%	72.26%
30 Jun, 22	1.59%	69.63%
31 Mar, 22	1.51%	39.10%
31 Dec, 21	1.97%	268.68%
30 Sep, 21	0.86%	-

As of 30 Jun 24, HCW Biologics is held by 1.44% institutional shareholders, representing a 15.33% growth compared to 31 Mar 24.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 24	1	-85.71%
31 Mar, 24	7	-36.36%
31 Dec, 23	11	83.33%
30 Sep, 23	6	20.00%
30 Jun, 23	5	-
31 Mar, 23	5	-28.57%
31 Dec, 22	7	75.00%
30 Sep, 22	4	-50.00%
30 Jun, 22	8	-
31 Mar, 22	8	-11.11%
31 Dec, 21	9	12.50%
30 Sep, 21	8	-

1 institutional shareholders have increased their position in HCWB stock as of 30 Jun 24 compared to 7 in the previous quarter (a -85.71% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 24	1	-80.00%
31 Mar, 24	5	66.67%
31 Dec, 23	3	50.00%
30 Sep, 23	2	-
30 Jun, 23	2	-
31 Mar, 23	2	-
31 Dec, 22	2	-
30 Sep, 22	2	100.00%
30 Jun, 22	1	-
31 Mar, 22	1	-
31 Dec, 21	1	-
30 Sep, 21	-	-

1 institutional shareholders have reduced their position in HCWB stock as of 30 Jun 24 compared to 5 in the previous quarter (a -80.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 24	3	-84.21%	535,042	-51.36%	1.44%	15.33%	1	-85.71%	1	-80.00%
31 Mar, 24	19	5.56%	1,100,110	3.30%	3.06%	34.85%	7	-36.36%	5	66.67%
31 Dec, 23	18	28.57%	1,064,955	4.94%	2.96%	37.12%	11	83.33%	3	50.00%
30 Sep, 23	14	16.67%	1,014,821	1.46%	2.83%	36.37%	6	20.00%	2	-
30 Jun, 23	12	-7.69%	1,000,256	14.36%	2.79%	46.92%	5	-	2	-
31 Mar, 23	13	-7.14%	874,657	11.99%	2.44%	51.39%	5	-28.57%	2	-
31 Dec, 22	14	27.27%	781,012	19.33%	2.18%	65.29%	7	75.00%	2	-
30 Sep, 22	11	-8.33%	654,478	14.95%	1.83%	72.26%	4	-50.00%	2	100.00%
30 Jun, 22	12	-	569,364	5.32%	1.59%	69.63%	8	-	1	-
31 Mar, 22	12	9.09%	540,609	46.50%	1.51%	39.10%	8	-11.11%	1	-
31 Dec, 21	11	37.50%	369,016	129.83%	1.97%	268.68%	9	12.50%	1	-
30 Sep, 21	8	-	160,563	-	0.86%	-	8	-	-	-

HCW Biologics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Sep 18, 2023	Wong Hing C	director, officer	Chief Executive Officer	P-Purchase	Buy	1,800	$2.08	$3.74K	15,314,868
Sep 15, 2023	Winer Gary M	director	-	P-Purchase	Buy	879	$2.05	$1.80K	17,000

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Sep 18, 2023	Wong Hing C	director, officer	Chief Executive Officer	P-Purchase	Buy	1,800	$2.08	$3.74K	15,314,868
Sep 15, 2023	Winer Gary M	director	-	P-Purchase	Buy	879	$2.05	$1.80K	17,000

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Dec 11, 2023	Rhode Peter	officer	See Remarks	M-Exempt	Sell	14,000	$0.14	$1.96K	22,427
Dec 11, 2023	Flowers Lee	officer	SVP of Business Development	M-Exempt	Sell	7,501	$0.14	$1.05K	-
Nov 20, 2023	Rhode Peter	officer	See Remarks	M-Exempt	Sell	15,000	$0.14	$2.10K	36,427
Oct 23, 2023	Byam Rebecca	officer	Chief Financial Officer	M-Exempt	Sell	47,249	$0.14	$6.61K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Jun 17, 2024	Giles Lisa M.	director	-	A-Award	Buy	12,500	$1.12	$14.00K	12,500
Jun 17, 2024	GARRETT SCOTT T	director	-	A-Award	Buy	12,500	$1.12	$14.00K	12,500
Jun 17, 2024	Greene Rick S.	director	-	A-Award	Buy	12,500	$1.12	$14.00K	12,500
Jun 17, 2024	Winer Gary M	director	-	A-Award	Buy	12,500	$1.12	$14.00K	12,500
Feb 22, 2024	Wong Hing C	director, officer	Chief Executive Officer	A-Award	Buy	739,288	$1.40	$1.04M	16,054,156
Feb 22, 2024	Greene Rick S.	director	-	A-Award	Buy	35,714	$1.40	$50.00K	44,125
Feb 22, 2024	Giles Lisa M.	director	-	A-Award	Buy	35,715	$1.40	$50.00K	35,815
Feb 22, 2024	GARRETT SCOTT T	director	-	A-Award	Buy	142,858	$1.40	$200.00K	267,858
Feb 22, 2024	Flowers Lee	officer	SVP of Business Development	A-Award	Buy	71,429	$1.40	$100.00K	190,238
Feb 22, 2024	Byam Rebecca	officer	Chief Financial Officer	A-Award	Buy	760,714	$1.40	$1.06M	1,381,909
Dec 11, 2023	Rhode Peter	officer	See Remarks	M-Exempt	Buy	14,000	$0.14	$1.96K	77,500
Dec 11, 2023	Rhode Peter	officer	See Remarks	M-Exempt	Sell	14,000	$0.14	$1.96K	22,427
Dec 11, 2023	Flowers Lee	officer	SVP of Business Development	M-Exempt	Buy	7,501	$0.14	$1.05K	118,809
Dec 11, 2023	Flowers Lee	officer	SVP of Business Development	M-Exempt	Sell	7,501	$0.14	$1.05K	-
Nov 20, 2023	Rhode Peter	officer	See Remarks	M-Exempt	Buy	15,000	$0.14	$2.10K	63,500
Nov 20, 2023	Rhode Peter	officer	See Remarks	M-Exempt	Sell	15,000	$0.14	$2.10K	36,427
Oct 23, 2023	Byam Rebecca	officer	Chief Financial Officer	M-Exempt	Buy	47,249	$0.14	$6.61K	621,195
Oct 23, 2023	Byam Rebecca	officer	Chief Financial Officer	M-Exempt	Sell	47,249	$0.14	$6.61K	-
Sep 18, 2023	Wong Hing C	director, officer	Chief Executive Officer	P-Purchase	Buy	1,800	$2.08	$3.74K	15,314,868
Sep 15, 2023	Winer Gary M	director	-	P-Purchase	Buy	879	$2.05	$1.80K	17,000

The last insider sell of HCW Biologics's stock was made by Rhode Peter on Dec 11 2023, selling 14,000 shares at $0.14 per share (valued at $1.96K). The last insider buy of HCWB was made by Wong Hing C on Sep 18 2023, buying 1,800 shares at $2.08 per share (worth $3.74K).

HCW Biologics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	6	-	-
Q4 2023	4	4	100.00%
Q3 2023	16	-	-
Q2 2023	22	1	2200.00%
Q4 2022	1	1	100.00%
Q3 2022	5	-	-
Q2 2022	16	-	-
Q1 2022	2	2	100.00%
Q4 2021	6	4	150.00%
Q3 2021	31	24	129.17%

6 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by HCW Biologics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q1 2024	-	-	-
Q4 2023	-	-	-
Q3 2023	16	-	-
Q2 2023	17	-	-
Q4 2022	-	-	-
Q3 2022	5	-	-
Q2 2022	9	-	-
Q1 2022	-	-	-
Q4 2021	1	-	-
Q3 2021	18	-	-

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of HCW Biologics's stocks.

HCW Biologics Peer Ownership

Ticker	Company
CYT	Cyteir Therapeutics, Inc.
PMVP	PMV Pharmaceuticals, Inc.
IPSC	Century Therapeutics, Inc.
CSBR	Champions Oncology, Inc.
MNOV	MediciNova, Inc.
PHVS	Pharvaris N.V.
RZLT	Rezolute, Inc.
PEPG	PepGen Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
MOLN	Molecular Partners AG
PRDS	Pardes Biosciences, Inc.
STTK	Shattuck Labs, Inc.
ELYM	Eliem Therapeutics, Inc.

HCWB Ownership FAQ

Who Owns HCW Biologics?

HCW Biologics is owned by institutional shareholders (1.44%), insiders (52.30%), and public (46.26%). The largest institutional shareholder of HCW Biologics is AVANTAX PLANNING PARTNERS, INC. (0.75% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.04% of total shares).

Who are the major institutional shareholders of HCW Biologics?

HCW Biologics's major institutional shareholders are AVANTAX PLANNING PARTNERS, INC., HIGHTOWER ADVISORS, LLC, GEODE CAPITAL MANAGEMENT, LLC, CRESSET ASSET MANAGEMENT, LLC, and PULLEN INVESTMENT MANAGEMENT, LLC. The top five shareholders own together 2.28% of the company's share outstanding.

How many HCW Biologics shareholders are there?

As of Jun 2024, there are 3 institutional shareholders of HCW Biologics.

What percentage of HCW Biologics is owned by AVANTAX PLANNING PARTNERS, INC?

AVANTAX PLANNING PARTNERS, INC owns 279.54K shares of HCW Biologics, representing 0.75% of the company's total shares outstanding, valued at $180.86K (as of Jun 2024).

What percentage of HCW Biologics is owned by HIGHTOWER ADVISORS, LLC?

As of Jun 2024, HIGHTOWER ADVISORS, LLC holds 180.81K shares of HCW Biologics (HCWB), compromising 0.49% of the company, valued at $117K.

What percentage of HCW Biologics is owned by GEODE CAPITAL MANAGEMENT, LLC?

GEODE CAPITAL MANAGEMENT, LLC is the third largest holder of HCW Biologics. The company owns 170.38K of the company's shares outstanding (worth $110.27K).